Trial Profile
A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination With Melphalan and Dexamethasone in Subjects With Newly-diagnosed Light-chain (AL)-Amyloidosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Sep 2014
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone; Melphalan
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 10 Sep 2014 New trial record